Pelthos Therapeutics Inc. — Form 8-K Summary
Event and reporting period: Filed October 1, 2026, reporting actions taken at the September 29, 2026 annual meeting. This is a current-event filing, not a periodic financial report.
Business and financial information
The filing reports corporate governance and stockholder-vote matters. It does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating results, and does not give comparable-period financial data.
Material developments
- Stockholders approved the 2026 Equity Incentive Plan, which became effective immediately and replaces the 2023 Equity Incentive Plan, as amended and restated. The filing refers to the proxy statement and Exhibit 10.1 for plan terms.
- All eight director nominees were elected to serve until the 2027 annual meeting or until their successors are elected and qualified, or earlier resignation or removal.
- Stockholders ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Annual meeting results
| Proposal | Result | Votes |
|---|---|---|
| Director elections | All eight nominees elected | For votes ranged from 2,775,221 to 2,885,576; broker non-votes: 510,173 per nominee |
| Auditor ratification | Approved | 3,394,740 for; 1 against; 1,353 abstentions |
| 2026 Equity Incentive Plan | Approved | 2,698,543 for; 187,365 against; 13 abstentions; 510,173 broker non-votes |
Quorum: holders representing 3,396,094 votes, reported as 70.0% of voting power, were present in person or by proxy. The record date was August 4, 2026.
Outlook, risks, and unusual items
The filing provides no financial guidance, operating outlook, management commentary, or discussion of contingencies. The principal reported change is adoption of the new equity incentive plan; its detailed terms are not reproduced in the filing text.
Key facts for investors to verify
- Review Exhibit 10.1 and the August 18, 2026 proxy statement for the plan’s share reserve, eligibility, award terms, and potential dilution.
- Confirm the voting-power calculation and record-date share counts against the proxy statement, including the treatment of Series A Preferred Stock on an as-converted basis.
- Review subsequent filings for equity awards issued under the 2026 Plan and any resulting dilution.